How COVID-19 Has Created a 'Shadow Curve' in the Treatment of Cancer and Other Diseases

Video

The impact of the COVID-19 pandemic on the cancer landscape has lead to enormous challenges for patients and professionals alike, but the impact of the pandemic will be felt on cancer care for years to come.

By disrupting the screening and treatment schedules of millions of Americans, the COVID-19 pandemic has created what one expert refers to as a ‘shadow curve’ of medical conditions such as cancer that are on the rise in the background while the virus takes center stage.

CURE®’s sister publication, Cancer Network, recently spoke with Dr. Pat Basu, president and CEO of Cancer Treatment Centers of America, about what this phenomenon is and how it could impact patients in the coming months and years.

Cancer Network: First off, can you explain what you refer to in your op-ed as the ‘shadow curve’?

Basu: Sure. So, the shadow curve, for me, really is a phrase that captures the idea that, with COVID, we've been talking about flattening the COVID curve, which is perfectly appropriate, as COVID is obviously a very serious infectious disease. But in the background, a shadow curve has been rising. And to me, that is all the diseases that are being disrupted and not treated while we've disrupted the American health care system.

So, cancer is certainly at the top of the list, but (also) heart disease, neurologic issues (etc.). You can imagine that, with hundreds of thousands or millions of those types of cases, it's almost like a tidal wave that's kind of building in the background. And so that's what I refer to as the shadow curve, all of the other medical conditions outside of COVID that are deadly and that are rising in the background.

In speaking with some other doctors, we've been told that these rescheduled appointments have already become overwhelming to the system. What will happen if this continues for the long term?

In the long term, my personal goal is to prevent a study being written in the year 2023 where we look back and say, in 2020, we missed 500,000 cancers, and half a million other heart conditions and other things that have led to increased debt and increased worsening of quality of life and worse mortality and morbidity in the future. And to me, that could occur in a few ways:

Number one, the direct lack of screenings and diagnoses. It's been estimated already that potentially over 100,000 cancer cases have been missed, just from the direct aspect of missed screenings. But our American health care system, as you know, is so fragmented as it is. Think about the average patient who had a doctor's appointment scheduled in April or had a mammogram scheduled in May. In a perfect world, you would say, on June 1, or on July 1, come back and get that done. Unfortunately, we know that our American health care system is horrible at continuity of care. And so, what ends up happening is the doctor's office ends up looking at that patient's record and saying, “Oh, well, you know what, they missed their mammogram last year, they're 2021.” And so, these things are going to get pushed out further and further.

And then finally, of course, patients are disrupted with their lifestyle, or they don't want to go in. So, for direct screenings, for indirect diagnosis of disease, and just for general disruption due to patient preference or physician preference, we're sadly missing a lot of diagnoses and the resulting therapy will be unfortunately in a worse position.

Related Videos
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Image of a woman with black hair.
Image of a woman with brown shoulder-length hair in front of a gray background that says CURE.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE